| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $11.30B | +8.9% |
| R&D Expense | $228.0M | +11.2% |
| SG&A Expense | $1.15B | +3.9% |
| Operating Income | $2.40B | +3.8% |
| Interest Expense | $727.0M | -11.1% |
| Pre-tax Income | $1.96B | +10.4% |
| Income Tax | $208.0M | -39.5% |
| Net Income | $1.45B | +18.4% |
| EPS (Basic) | $1.97 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.65B | -28.5% |
| Accounts Receivable | $417.0M | -13.8% |
| Inventory | $41.0M | +7.9% |
| Current Assets | $4.29B | -25.7% |
| Total Assets | $20.67B | -5.1% |
| Current Liabilities | $5.80B | +31.2% |
| Long-term Debt | $10.59B | -12.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Capital Expenditures | $1.57B | +54.1% |
| +23.1% |
| EPS (Diluted) | $1.96 | +22.5% |
| Total Liabilities |
| $17.51B |
| -1.0% |
| Stockholders' Equity | $2.88B | -30.0% |